Indication
Malignant Mesothelioma
Aliases
Malignant Mesothelioma (MM)
3 clinical trials
3 products
Clinical trial
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 ExpressionStatus: Recruiting, Estimated PCD: 2028-06-01
Product
A2B694Clinical trial
Phase II Evaluation of Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage MesotheliomaStatus: Recruiting, Estimated PCD: 2025-12-01
Product
Decitabine/cedazuridineClinical trial
An Efficacy and Safety Study of Avelumab Plus SBRT in Malignant Mesothelioma (MPM)Status: Completed, Estimated PCD: 2023-01-20
Product
Avelumab